Event Report: How is research in Ireland addressing the challenges of bowel cancer?

COLOSSUS, one of MErCuRIC’s “Related Projects” recently hosted a public event in Dublin and invited Coordinator Sandra Van Schaeybroeck to participate.

Professor Annette Byrne, Head of the Royal College of Surgeons Ireland (RSCI) Precision Cancer Medicine Group and Coordinator of the EC funded multi-million Euro Colorectal Cancer Research Programme COLOSSUS hosted and chaired the event at the RCSI on the 30th April 2019 in Dublin.   The meeting provided a fitting finale to Bowel Cancer Awareness Month throughout Europe.  She welcomed a packed audience and introduced three keynote speakers.

Coordinator of the MErCuRIC Project, Dr Sandra Van Schaeybroeck from Queen’s University, Belfast gave a comprehensive and enthralling lecture which summarised the aetiology of bowel cancer and provided current statistics on its prevalence in Europe and throughout the world.  She elaborated on current treatment options and new clinical approaches to the four stages of the disease.  The importance of early screening was emphasised given the lower survival rates from the more advanced stages, particularly Stage 4 where the cancer has spread to major organs such as the liver.  For example, 6 out of 10 colorectal cancer deaths could be prevented if all men and women over 50 years of age were screened routinely using the newest techniques.  Additionally, the removal of precancerous polyps reduced the probability of contracting colon cancer by 70%.

A major research challenge internationally has been to improve the survival outcome of stage 4 patients with genetic aberrations in KRAS/BRAF genes.  These patients are often resistant to historical chemotherapy options.  The MErCuRIC study, a major European collaboration between several countries, including the UK, Belgium, Spain, France, Italy, Czech Republic and Ireland, is investigating a unique combination therapy of immunotherapy and chemotherapy in order to treat patients with the above aberrations.  The project is now in Phase 2 and 82 patients have been recruited.

The next speaker, Dr Ian Miller (RCSI), delineated exciting new research work in their laboratories where there has been a particular focus on new developments in the search for more sensitive and specific biomarkers in order to predict particular types of colorectal cancer.  This lecture complemented the work of the previous speaker in stressing the importance of more precise identification of biomarkers which had the potential to pinpoint more effective therapies for the treatment and control of bowel cancer.

The final speaker, Dr Orla Casey (Cancer Trials Ireland), detailed the comprehensive programme of research which they had supported in recent years.  Additional to a large number of major clinical trials, there had been considerable effort expended on translational studies typified, for example, by the COLOSSUS study outlined by the Chairperson, Professor Annette Byrne, at the beginning of the session.  Biobank studies were continuing to prove of extreme value in making the most effective and efficient use of large datasets that were already available from patients.

The event, organised by Danielle Nicholson of Pintail Limited with assistance from Dr Alice O’Farrell (RCSI), was a major success and captivated a very attentive audience of health professionals and patients.  Dr Ed Goodall of Digestive Cancers Europe (DiCE) and the Northern Ireland Cancer Research Forum (NICRF) Patient Advocacy Representative commented, ‘The event did indeed provide a fitting finale to Bowel Cancer Awareness Month.  For Health Authorities the message was clear and explicit.  Instigate screening programmes for all male and females over 50 years of age and back them up with comprehensive awareness campaigns for potential patients.  Secondly, support the exciting research being conducted in our major universities prevent, diagnose and treat more effectively the various types and stages of colorectal cancer’.

Ed Goodall and Margaret Grayson catch up before the event

Sandra Van Schaeybroeck, Queen’s University Belfast at the speaker’s podium

Annette Byrne, RCSI and COLOSSUS Coordinator thanks speakers and attendees

MErCuRIC Coordinator joins forces for Bowel Cancer Awareness Month 2019

Prof. Sandra Van Schaeybroeck from Queen’s University Belfast, the Coordinator of the MErCuRIC project will join researchers involved in the COLOSSUS Project to facilitate a public forum in Dublin on 30 April 2019. In Ireland, April is “Bowel Cancer Awareness Month”. The event: “Colorectal Cancer- How is research in Ireland addressing the challenges?” will take place at the Royal College of Surgeons in Ireland (RCSI) from 18:30- 19:30. Prof Van Schaeybroeck’s talk is entitled “Current treatment options and clinical research approaches“. Sandra will provide a clinicians point of view and discuss the personalized medicine approach to treating colorectal, or bowel cancer. Other speakers include Prof Annette Byrne, Head of the RCSI Precision Cancer Medicine Group & Coordinator of the COLOSSUS Project, Dr Ian Miller, RCSI Precision Cancer Medicine Group and Dr Verena Murphy, Translational Research Leader at Cancer Trials Ireland.  

One of MErCuRIC’s Related Projects, COLOSSUS is an EU-funded Horizon 2020 project that aims to provide new and more effective ways to classify patients with a specific type of colorectal cancer (microsatellite stable RAS mutant metastatic colorectal cancer or MSS RAS mt mCRC) and to develop better treatments for them. The ultimate goal is to deliver a personalised medicine approach for patients with MSS RAS mt mCRC that is currently not available.

For more information, details about the event and to register, please visit Eventbrite.

Partner UNITO adds to MErCuRIC list of publications

Two new research studies with acknowledgement to MErCuRIC have recently been published by our partners at the University of Torino (UNITO):

  • Truini A, Germano G, Bardelli A. Inactivation of DNA repair-prospects for boosting cancer immune surveillance. Genome Med. 2018 Nov 28;10(1):91. doi: 10.1186/s13073-018-0603-9. PubMed PMID: 30486892; PubMed Central PMCID: PMC6260742.
  • Germano G, Amirouchene-Angelozzi N, Rospo G, Bardelli A. The Clinical Impact of the Genomic Landscape of Mismatch Repair-Deficient Cancers. Cancer Discov. 2018 Dec;8(12):1518-1528. doi: 10.1158/2159-8290.CD-18-0150. Epub 2018 Nov 15. Review. PubMed PMID: 30442708.

Congratulations to all researchers involved!

To read more about these and other MErCuRIC-funded scientific publications, please visit http://mercuric.eu/project/publications/

MErCuRIC progress and goals elucidated at EORTC-NCI-AACR Symposium

MErCuRIC Coordinator Prof Sandra Van Schaeybroeck (QUB) and PI Prof Richard Wilson (BHSCT) presented recent project findings at the EORTC NCI AACR symposium in Dublin. This year’s meeting theme was “Molecular Targets and Cancer Therapeutics”. The research poster entitled “MErCuRIC1: A phase 1 Multi-Centre Study of Crizotinib (cMET inhibitor) Combined with Binimetinib (MEK1/2 inhibitor) in Patients with Advanced Solid Tumours” was presented on Friday, November 16, 2018. Herein, the first results from the MErCuRIC dose escalation and dose expansion study of the combination of MEK and MET in RASmt colorectal cancer patients were presented. The poster (link below) also showed the first data on MET as potential biomarker using samples of the MErCuRIC clinical trial. Poster discussion with meeting attendees focussed on the importance to explore further mechanisms of response/resistance to this MEK + MET combination, using available clinical samples and pre-clinical translational studies.

Sandra Van Schaeybroeck commented: “I believe that we can learn a lot from the MErCuRIC clinical study. We want to nail down the role of MET, at gene, mRNA and protein level as a prognostic and predictive biomarker in early stage and metastatic CRC. We want to underpin mechanisms of intrinsic CRC tumour resistance to MEK and MET inhibition, that will inform future studies with MEK and/or MET inhibition, not only in CRC but also other tumour types”.

MErCuRIC EORTC-NCI-AACR 2018 Poster v0.5 SVS RHW